| First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers BI Sikic, N Lakhani, A Patnaik, SA Shah, SR Chandana, D Rasco, ... Journal of Clinical Oncology 37 (12), 946-953, 2019 | 525 | 2019 |
| Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ... The lancet oncology 21 (5), 645-654, 2020 | 412 | 2020 |
| The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients B Alman, S Attia, C Baumgarten, C Benson, JY Blay, S Bonvalot, ... European Journal of Cancer 127, 96-107, 2020 | 394 | 2020 |
| Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study M Gounder, P Schöffski, RL Jones, M Agulnik, GM Cote, VM Villalobos, ... The Lancet Oncology 21 (11), 1423-1432, 2020 | 323 | 2020 |
| NCCN guidelines insights: bone cancer, version 2.2017 JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ... Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 2017 | 304 | 2017 |
| Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors HA Burris, JR Infante, SM Ansell, JJ Nemunaitis, GR Weiss, VM Villalobos, ... Journal of Clinical Oncology 35 (18), 2028-2036, 2017 | 144 | 2017 |
| Current state of imaging protein-protein interactions in vivo with genetically encoded reporters V Villalobos, S Naik, D Piwnica-Worms Annu. Rev. Biomed. Eng. 9 (1), 321-349, 2007 | 128 | 2007 |
| Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma WD Tap, VM Villalobos, GM Cote, H Burris, F Janku, O Mir, M Beeram, ... Journal of Clinical Oncology 38 (15), 1693-1701, 2020 | 120 | 2020 |
| Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin KG Pinney, MP Mejia, VM Villalobos, BE Rosenquist, GR Pettit, ... Bioorganic & medicinal chemistry 8 (10), 2417-2425, 2000 | 120 | 2000 |
| Single gene prognostic biomarkers in ovarian cancer: a meta-analysis S Willis, VM Villalobos, O Gevaert, M Abramovitz, C Williams, BI Sikic, ... PloS one 11 (2), e0149183, 2016 | 114 | 2016 |
| A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib KN Ganjoo, VM Villalobos, A Kamaya, GA Fisher, JE Butrynski, ... Annals of oncology 25 (1), 236-240, 2014 | 109 | 2014 |
| Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study YK Kang, S George, RL Jones, P Rutkowski, L Shen, O Mir, S Patel, ... Journal of Clinical Oncology 39 (28), 3128-3139, 2021 | 99 | 2021 |
| Dual-color click beetle luciferase heteroprotein fragment complementation assays V Villalobos, S Naik, M Bruinsma, RS Dothager, MH Pan, M Samrakandi, ... Chemistry & biology 17 (9), 1018-1029, 2010 | 90 | 2010 |
| Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptake ST Gammon, VM Villalobos, JL Prior, V Sharma, D Piwnica-Worms Bioconjugate chemistry 14 (2), 368-376, 2003 | 79 | 2003 |
| Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES)(NCT02601950). S Stacchiotti, P Schoffski, R Jones, M Agulnik, VM Villalobos, TM Jahan, ... Journal of Clinical Oncology 37 (15_suppl), 11003-11003, 2019 | 76 | 2019 |
| Identification of ovarian cancer driver genes by using module network integration of multi-omics data O Gevaert, V Villalobos, BI Sikic, SK Plevritis Interface focus 3 (4), 20130013, 2013 | 71 | 2013 |
| Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the … LM Kopp, S Malempati, M Krailo, Y Gao, A Buxton, BJ Weigel, ... European Journal of Cancer 121, 177-183, 2019 | 62 | 2019 |
| Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor VM Villalobos, F Hall, A Jimeno, L Gore, K Kern, R Cesari, B Huang, ... Annals of Surgical Oncology 25, 768-775, 2018 | 62 | 2018 |
| Permeation peptide conjugates for in vivo molecular imaging applications KE Bullok, ST Gammon, S Violini, AM Prantner, VM Villalobos, V Sharma, ... Molecular Imaging 5 (1), 7290.2006. 00001, 2006 | 59 | 2006 |
| First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors GD Demetri, JJ Luke, A Hollebecque, JD Powderly, AI Spira, V Subbiah, ... Clinical Cancer Research 27 (13), 3556-3566, 2021 | 57 | 2021 |
